Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial
PLOS Medicine · 2024
DOI: 10.1371/journal.pmed.1004356 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, 2024. Verfasst von Fred C Semitala und 24 weiteren Autor:innen. Beteiligte Einrichtung: Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda. Hauptthemen laut MEDLINE: Tuberculosis, Latent Tuberculosis, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies. Methods and findings In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (≥11 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher’s exact test (two-sided α = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] p < 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] p < 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] p < 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings.
Conclusions
Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers. Trial Registration ClinicalTrials.gov NCT03934931 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Makerere University Joint AIDS Program, Kampala Uganda.
- Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.
- Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
- Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
ORCID-Profile: Jillian L Kadota, Allan Musinguzi, Joan Ritar Kasidi, Suzan Nakasendwa, Devika Patel, Moses R Kamya, Patrick Pj Phillips, Anne Katahoire, Christopher A Berger, David W Dowdy, Adithya Cattamanchi
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Semitala, F. C., Kadota, J. L., Musinguzi, A., Welishe, F., Nakitende, A., Akello, L., Kunihira Tinka, L., Nakimuli, J., Ritar Kasidi, J., Bishop, O., Nakasendwa, S., Baik, Y., Patel, D., Sammann, A., Nahid, P., Belknap, R., Kamya, M. R., Handley, M. A., Phillips, P. P., …, & Cattamanchi, A. (2024). Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004356
Vancouver
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, et al. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004356
BibTeX
@article{Semitala2024,
author = {Semitala, Fred C and Kadota, Jillian L and Musinguzi, Allan and Welishe, Fred and Nakitende, Anne and Akello, Lydia and Kunihira Tinka, Lynn and Nakimuli, Jane and Ritar Kasidi, Joan and Bishop, Opira and Nakasendwa, Suzan and Baik, Yeonsoo and Patel, Devika and Sammann, Amanda and Nahid, Payam and Belknap, Robert and Kamya, Moses R and Handley, Margaret A and Phillips, Patrick Pj and Katahoire, Anne and Berger, Christopher A and Kiwanuka, Noah and Katamba, Achilles and Dowdy, David W and Cattamanchi, Adithya},
title = {Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial},
journal = {PLOS Medicine},
year = {2024},
doi = {10.1371/journal.pmed.1004356}
}
EUVIMED